Taurodeoxycholat-d4 sodium
Taurodeoxycholat-d4 sodium is the deuterium labeled Taurodeoxycholate sodium (HY-128853). Taurodeoxycholate sodium salt is a bile salt-related anionic detergent. Taurodeoxycholate sodium salt is formed in the liver by conjugation of deoxycholate with Taurine (HY-B0351). Taurodeoxycholate sodium salt is used for isolation of membrane proteins including inner mitochondrial membrane proteins. Taurodeoxycholate (TDCA) exhibits anti-inflammatory and neuroprotective effects.
For research use only. We do not sell to patients.
- Formula: C26H40D4NNaO6S
- Molecular Weight:525.71
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All Endogenous Metabolite Isoforms
More
Biological Activity
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
Unlabeled Cas 1180-95-6
-
Molecular Weight 525.71
-
Formula C26H40D4NNaO6S
-
SMILES
C[C@H](CCC(NC([2H])([2H])C([2H])([2H])S(=O)(O[Na])=O)=O)[C@H]1CC[C@@]2([H])[C@]3([H])CC[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@]12C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Villavicencio-Queijeiro A, et al. The fully-active and structurally-stable form of the mitochondrial ATP synthase of Polytomella sp. is dimeric. J Bioenerg Biomembr. 2009 Feb;41(1):1-13. [Content Brief]
[2]. Kispal G, et al. Isolation and characterization of 3-hydroxyacyl coenzyme A dehydrogenase-binding protein from pig heart inner mitochondrial membrane. J Biol Chem. 1986 Oct 25;261(30):14209-13. [Content Brief]
[3]. Choi HJ, et al. Evaluation of acute and subacute toxicity of sodium taurodeoxycholate in rats. Drug Chem Toxicol. 2021 May;44(3):268-276. [Content Brief]
[4]. Sato H, et al. Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies. J Med Chem. 2008 Mar 27;51(6):1831-41. [Content Brief]
[5]. Gertzen CG, et al. Mutational mapping of the transmembrane binding site of the G-protein coupled receptor TGR5 and binding mode prediction of TGR5 agonists. Eur J Med Chem. 2015 Nov 2;104:57-72. [Content Brief]
[6]. Benz C, et al. Effect of tauroursodeoxycholic acid on bile acid-induced apoptosis in primary human hepatocytes. Eur J Clin Invest. 2000 Mar;30(3):203-9. [Content Brief]
[7]. Xie Q, et al. Effect of tauroursodeoxycholic acid on endoplasmic reticulum stress-induced caspase-12 activation. Hepatology. 2002 Sep;36(3):592-601. [Content Brief]
[8]. Yamaguchi J, et al. Taurodeoxycholate increases intestinal epithelial cell proliferation through c-myc expression. Surgery. 2004 Feb;135(2):215-21. [Content Brief]
[9]. Zou Y, et al. Taurodeoxycholate ameliorates DSS-induced colitis in mice. Int Immunopharmacol. 2023 Sep;122:110628. [Content Brief]
[10]. Keene CD, et al. A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease. Exp Neurol. 2001 Oct;171(2):351-60. [Content Brief]
[11]. Keene CD, et al. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10671-6. [Content Brief]
[12]. Chang S, et al. Taurodeoxycholate Increases the Number of Myeloid-Derived Suppressor Cells That Ameliorate Sepsis in Mice. Front Immunol. 2018 Sep 18;9:1984. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Taurodeoxycholat-d4 sodium Related Classifications
HY-128853S1 Related Classifications
Powered by Bioz